Multicolor, single active layer electrochromic devices

    公开(公告)号:US11156891B1

    公开(公告)日:2021-10-26

    申请号:US16161667

    申请日:2018-10-16

    Inventor: Manoj Kumar Ram

    Abstract: In one embodiment, an electrochromic device includes a single unitary active layer including a dye having a nitrogen group and a conducting polymer having a nitrogen group, wherein the active layer has a first color in an oxidized state and a second color in a reduced state, and wherein the electrochromic device comprises no other active layer.

    Detection of cancer by elevated levels of bcl-2

    公开(公告)号:US11156613B2

    公开(公告)日:2021-10-26

    申请号:US16190475

    申请日:2018-11-14

    Inventor: Patricia A. Kruk

    Abstract: The present invention relates to a method for the diagnosis, prognosis, and monitoring of cancer, such as early or late stage ovarian cancer, in a subject by detecting Bcl-2 in a biological sample from the subject, preferably a urine or blood sample. Bcl-2 may be measured using an agent that detects or binds to Bcl-2 protein or an agent that detects or binds to encoding nucleic acids, such as antibodies specifically reactive with Bcl-2 protein or a portion thereof. The invention further relates to kits for carrying out the methods of the invention. The invention further relates to a device for the rapid detection of Bcl-2 in a bodily fluid and methods for rapidly measuring Bcl-2 in a bodily fluid.

    Systems and methods for expert-assisted classification

    公开(公告)号:US11138473B1

    公开(公告)日:2021-10-05

    申请号:US16511255

    申请日:2019-07-15

    Abstract: Systems and methods for expert-assisted classification are described herein. An example method for evaluating an expert-assisted classifier can include providing a cascade classifier including a plurality of classifier stages; and providing a simulated expert stage between at least two of the classifier stages. The simulated expert stage can be configured to validate or contradict an output of one of the at least two classifier stages. The method can also include classifying each of a plurality of records into one of a plurality of categories using the cascade classifier combined with the simulated expert stage; and determining whether the simulated expert stage improves performance of the cascade classifier.

    Systems and methods for neurologic vibratory sense evaluation

    公开(公告)号:US11083373B1

    公开(公告)日:2021-08-10

    申请号:US16359343

    申请日:2019-03-20

    Abstract: In one embodiment, a system for neurologic vibratory sense evaluation includes a vibration article configured to attach to a body part of a patient under evaluation, the vibration article comprising a vibration element configured to vibrate against the body part, a control module configured to control an amplitude of vibrations generated by the vibration element, and a patient input device configured to enable a patient to start and stop an evaluation session, wherein starting the session in a first mode of operation causes the vibration element to initially vibrate at a relatively high amplitude that gradually decreases and wherein starting the session in a second mode of operation causes the vibration element to initially vibrate at a relatively low amplitude that gradually increases.

    METHOD FOR DETECTION AND ANALYSIS OF CEREBROSPINAL FLUID ASSOCIATED UBE3A

    公开(公告)号:US20210208142A1

    公开(公告)日:2021-07-08

    申请号:US17180189

    申请日:2021-02-19

    Abstract: A method and kit for diagnosing Angelman Syndrome by detecting and analyzing ubiquitination of the UBE3A protein in cerebrospinal fluid is presented. CSF is collected from a patient and incubated with a substrate, such as S5a, and ubiquitin. Ubiquitination of the substrate by UBE3A is measured and compared to a control sample for biochemical diagnosis of Angelman Syndrome. A method of determining the efficacy of a treatment is also presented in which CSF is collected from the patient both prior to and after treatment and incubated with a substrate and ubiquitin. Ubiquitination of the substrate by UBE3A is measured and an increase in ubiquitination in the sample obtained after treatment as compared to the reference sample collected prior to treatment indicates efficacy of the treatment.

Patent Agency Ranking